Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Herpes Zoster (Shingles) - Pipeline Review, H2 2012
Publication Date Aug 2012
Publisher Global Markets Direct
Product Type Report
Pages 58
Single User License $ 2000.00
Site User License $ 4000.00
Corporate User License $ 6000.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Herpes Zoster (Shingles) - Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Herpes Zoster (Shingles) - Pipeline Review, H2 2012', provides an overview of the Herpes Zoster (Shingles) therapeutic pipeline. This report provides information on the therapeutic development for Herpes Zoster (Shingles), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles). 'Herpes Zoster (Shingles) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Herpes Zoster (Shingles).
- A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Herpes Zoster (Shingles) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Herpes Zoster (Shingles) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Herpes Zoster (Shingles) Therapeutic Products under Development, Key Players in Herpes Zoster (Shingles) Therapeutics, Herpes Zoster (Shingles) Pipeline Overview, Herpes Zoster (Shingles) Pipeline, Herpes Zoster (Shingles) Pipeline Assessment

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Zoster (Shingles) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Herpes Zoster (Shingles) 8
Herpes Zoster (Shingles) Therapeutics under Development by Companies 10
Herpes Zoster (Shingles) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Herpes Zoster (Shingles) Therapeutics - Products under Development by Companies 16
Herpes Zoster (Shingles) Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Herpes Zoster (Shingles) Therapeutics Development 18
GlaxoSmithKline plc 18
Merck & Co., Inc. 19
Inhibitex, Inc. 20
Clavis Pharma ASA 21
aRigen Pharmaceuticals, Inc. 22
Epiphany Biosciences, Inc. 23
EMS S.A. 24
Herpes Zoster (Shingles) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
FV-100 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ARYS-01 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CP-4018 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
EPB-348 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Zoster - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Varicella-Zoster Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ZOSTAVAX - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
V212 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Zostavax - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Famciclovir - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Herpes Zoster (Shingles) Therapeutics - Drug Profile Updates 45
Herpes Zoster (Shingles) Therapeutics - Discontinued Products 48
Herpes Zoster (Shingles) Therapeutics - Dormant Products 49
Herpes Zoster (Shingles) - Product Development Milestones 50
Featured News & Press Releases 50
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients 50
Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100 51
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients 52
Aug 23, 2010: GSK Initiates Phase III Clinical Trials To Develop Herpes Zoster Vaccine For Prevention Of Shingles 52
Jul 22, 2010: Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation Of Phase II Clinical Trial Of FV-100 53
Nov 18, 2009: Epiphany Announces Positive Results Of Its Drug Candidate Valomaciclovir From Its Phase 2b Trial In Shingles 53
Sep 09, 2008: Epiphany Biosciences Announces To Continue Phase 2 shingles Study After Interim Analysis 54
Nov 07, 2007: Epiphany Biosciences Reports Initiation And Enrollment In Valomaciclovir Study For Shingles 55
Dec 05, 2006: aRigen Group Announces Successful Phase II Study Of ARYS-01 (Sorivudine) Cream 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
List of Tables
Number of Products Under Development for Herpes Zoster (Shingles), H2 2012 8
Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
GlaxoSmithKline plc, H2 2012 18
Merck & Co., Inc., H2 2012 19
Inhibitex, Inc., H2 2012 20
Clavis Pharma ASA, H2 2012 21
aRigen Pharmaceuticals, Inc., H2 2012 22
Epiphany Biosciences, Inc., H2 2012 23
EMS S.A., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 29
Herpes Zoster (Shingles) Therapeutics - Drug Profile Updates 45
Herpes Zoster (Shingles) Therapeutics - Discontinued Products 48
Herpes Zoster (Shingles) Therapeutics - Dormant Products 49

List of Figures
List of Figures
Number of Products under Development for Herpes Zoster (Shingles), H2 2012 8
Products under Development for Herpes Zoster (Shingles) - Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 25
Assessment by Route of Administration, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Molecule Type, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 29

Title Date Price
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Medical Devices Market in Russia 2009-2013
By Infiniti Research Ltd
Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
Mar 2010 $1500.00
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances Profile
By GlobalData
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances ProfileSummary20/10 Perfect Vision AG is engaged in the development, manufacturing and marketing of innovative technologies for raisi ...Read More
Jan 2012 $250.00
2010 U.S. Ambulatory Surgical & Emergency Centers Industry Report
By Barnes Reports
The U.S Ambulatory Surgical & Emergency Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...Read More
Jan 2010 $149.00
2010 U.S. Biological Product Manufacturing Industry Report
By Barnes Reports
The U.S. Biological Product Manufacturing Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 ...Read More
Jan 2010 $149.00
2010 U.S. HMO Medical Centers Industry Report
By Barnes Reports
The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
Jan 2010 $149.00
2010 U.S. Home Health Care Services Industry Report
By Barnes Reports
The Home Health Care Services Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and ...Read More
Oct 2009 $149.00
2010 U.S. Kidney Dialysis Centers Industry Report
By Barnes Reports
The U.S Kidney Dialysis Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current an ...Read More
Jan 2010 $149.00
2010 U.S. Medical & Surgical Hospitals Industry Report
By Barnes Reports
The Medical & Surgical Hospitals Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current a ...Read More
Oct 2009 $149.00
2010 U.S. Medical Laboratories Industry Report
By Barnes Reports
The Medical Laboratories Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 2011 ...Read More
Oct 2009 $149.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z